sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.
|
lithium
|
escitalopram
|
EFFECT
|
Escitalopram_ddi.xml
|
DDI-DrugBank.d568.s12
|
DDI-DrugBank.d568.s12.p0
|
Metoprolol - Administration of 20 mg/day LEXAPRO for 21 days in healthy volunteers resulted in a 50% increase in Cmax and 82% increase in AUC of the beta-adrenergic blocker metoprolol (given in a single dose of 100 mg).
|
LEXAPRO
|
metoprolol
|
MECHANISM
|
Escitalopram_ddi.xml
|
DDI-DrugBank.d568.s35
|
DDI-DrugBank.d568.s35.p4
|
Simvastatin and Other Statins: Co-administration of bosentan decreased the plasma concentrations of simvastatin (a CYP3A4 substrate), and its active -hydroxy acid metabolite, by approximately 50%.
|
bosentan
|
simvastatin
|
MECHANISM
|
Bosentan_ddi.xml
|
DDI-DrugBank.d289.s25
|
DDI-DrugBank.d289.s25.p5
|
Lethargy and somnolence have been reported following doses of REVIA and thioridazine.
|
REVIA
|
thioridazine
|
EFFECT
|
Naltrexone_ddi.xml
|
DDI-DrugBank.d346.s3
|
DDI-DrugBank.d346.s3.p0
|
Cholestyramine resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine resin.
|
resin
|
cholestyramine
|
NONE
|
Cholestyramine_ddi.xml
|
DDI-DrugBank.d566.s2
|
DDI-DrugBank.d566.s2.p16
|
Other CNS depressant drugs (e.g. barbiturates, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with INAPSINE.
|
tranquilizers
|
INAPSINE
|
EFFECT
|
Droperidol_ddi.xml
|
DDI-DrugBank.d254.s0
|
DDI-DrugBank.d254.s0.p11
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
acetaminophen
|
Kaletra
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p71
|
Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or thioridazine) or lead to electrolyte abnormalities (such as diuretics or amphotericin B).
|
TRISENOX
|
diuretics
|
ADVISE
|
Arsenic trioxide_ddi.xml
|
DDI-DrugBank.d470.s1
|
DDI-DrugBank.d470.s1.p2
|
- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
|
Phenothiazines
|
trifluoperazine
|
NONE
|
Sulfapyridine_ddi.xml
|
DDI-DrugBank.d179.s21
|
DDI-DrugBank.d179.s21.p18
|
There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
|
erythromycin
|
alfentanil
|
INT
|
Erythromycin_ddi.xml
|
DDI-DrugBank.d397.s8
|
DDI-DrugBank.d397.s8.p5
|
The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .
|
ENABLEX
|
nelfinavir
|
ADVISE
|
Darifenacin_ddi.xml
|
DDI-DrugBank.d459.s0
|
DDI-DrugBank.d459.s0.p3
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
cyclosporine
|
protease inhibitors
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p716
|
Ethosuximide: Amphetamines may delay intestinal absorption of ethosuximide.
|
Amphetamines
|
ethosuximide
|
MECHANISM
|
Dextroamphetamine_ddi.xml
|
DDI-DrugBank.d236.s17
|
DDI-DrugBank.d236.s17.p2
|
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.
|
gentamicin
|
pentamidine
|
NONE
|
Cidofovir_ddi.xml
|
DDI-DrugBank.d260.s3
|
DDI-DrugBank.d260.s3.p27
|
Therefore, fenofibrate should be taken at least 1 hour before or 4-6 hours after a bile acid binding resin to avoid impeding its absorption .
|
fenofibrate
|
bile acid binding resin
|
ADVISE
|
Fenofibrate_ddi.xml
|
DDI-DrugBank.d283.s12
|
DDI-DrugBank.d283.s12.p0
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
lincomycin
|
sodium colistemethate
|
NONE
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s12
|
DDI-DrugBank.d60.s12.p86
|
In a single-dose crossover study examining lansoprazole 30 mg and omeprazole 20 mg each administered alone and concomitantly with sucralfate 1 gram, absorption of the proton pump inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate.
|
proton pump inhibitors
|
sucralfate
|
MECHANISM
|
Lansoprazole_ddi.xml
|
DDI-DrugBank.d431.s7
|
DDI-DrugBank.d431.s7.p9
|
- Lithium: Lithium should generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of lithium toxicity.
|
Lithium
|
bumetanide
|
ADVISE
|
Bumetanide_ddi.xml
|
DDI-DrugBank.d331.s3
|
DDI-DrugBank.d331.s3.p5
|
Acetazolamide increases lithium excretion and the lithium may be decreased.
|
Acetazolamide
|
lithium
|
MECHANISM
|
Acetazolamide_ddi.xml
|
DDI-DrugBank.d368.s12
|
DDI-DrugBank.d368.s12.p0
|
Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive Ortho-Novum produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.
|
bosentan
|
Ortho-Novum
|
MECHANISM
|
Bosentan_ddi.xml
|
DDI-DrugBank.d289.s6
|
DDI-DrugBank.d289.s6.p12
|
Vasopressors: Thyroxine increases the adrenergic effect of catecholamines such as epinephrine and norepinephrine.
|
Thyroxine
|
epinephrine
|
EFFECT
|
Liothyronine_ddi.xml
|
DDI-DrugBank.d54.s21
|
DDI-DrugBank.d54.s21.p3
|
Exert particular caution in combining chlorprothixene with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.
|
chlorprothixene
|
tricyclic antidepressants
|
ADVISE
|
Chlorprothixene_ddi.xml
|
DDI-DrugBank.d503.s7
|
DDI-DrugBank.d503.s7.p1
|
Therapeutic drug monitoring can avoid iatrogenic alterations caused by 99mTc-methylene diphosphonate (MDP)-gentamicin interaction.
|
99mTc-methylene diphosphonate
|
gentamicin
|
EFFECT
|
7632757.xml
|
DDI-MedLine.d89.s0
|
DDI-MedLine.d89.s0.p0
|
Cyclopentolate may interfere with the anti-glaucoma action of carbachol or pilocarpine;
|
Cyclopentolate
|
carbachol
|
EFFECT
|
Cyclopentolate_ddi.xml
|
DDI-DrugBank.d298.s0
|
DDI-DrugBank.d298.s0.p0
|
Rifampin: Following concomitant administration of a single dose of ARAVA to subjects receiving multiple doses of rifampin, M1 peak levels were increased (~40%) over those seen when ARAVA was given alone.
|
ARAVA
|
rifampin
|
MECHANISM
|
Leflunomide_ddi.xml
|
DDI-DrugBank.d41.s14
|
DDI-DrugBank.d41.s14.p3
|
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
|
fentanyl
|
saquinavir
|
MECHANISM
|
Saquinavir_ddi.xml
|
DDI-DrugBank.d124.s26
|
DDI-DrugBank.d124.s26.p129
|
Rifampin: Coadministration of rifampin and VIRACEPT resulted in an 82% decrease in nelfinavir plasma A.C.
|
Rifampin
|
nelfinavir
|
NONE
|
Nelfinavir_ddi.xml
|
DDI-DrugBank.d340.s32
|
DDI-DrugBank.d340.s32.p2
|
Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
|
caffeine
|
narcotic analgesic
|
EFFECT
|
Butalbital_ddi.xml
|
DDI-DrugBank.d559.s1
|
DDI-DrugBank.d559.s1.p17
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Topamax
|
clofibrate
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p436
|
It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.
|
tetracyclines
|
LEVULAN KERASTICK
|
EFFECT
|
Aminolevulinic acid_ddi.xml
|
DDI-DrugBank.d379.s1
|
DDI-DrugBank.d379.s1.p27
|
Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or aspirin potentiated the risk of bleeding.
|
psychotropic drugs
|
aspirin
|
EFFECT
|
Escitalopram_ddi.xml
|
DDI-DrugBank.d568.s5
|
DDI-DrugBank.d568.s5.p1
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
atorvastatin
|
vitamin C
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p638
|
Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone) and isoniazid may reduce the therapeutic effects of levodopa.
|
Dopamine D2 receptor antagonists
|
levodopa
|
EFFECT
|
Carbidopa_ddi.xml
|
DDI-DrugBank.d47.s2
|
DDI-DrugBank.d47.s2.p4
|
Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.
|
FACTIVE
|
omeprazole
|
MECHANISM
|
Gemifloxacin_ddi.xml
|
DDI-DrugBank.d347.s1
|
DDI-DrugBank.d347.s1.p2
|
Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
|
serotonin reuptake inhibitors
|
TIKOSYN
|
ADVISE
|
Dofetilide_ddi.xml
|
DDI-DrugBank.d558.s25
|
DDI-DrugBank.d558.s25.p40
|
Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
|
benzodiazepine class
|
barbiturates
|
EFFECT
|
Clonazepam_ddi.xml
|
DDI-DrugBank.d333.s7
|
DDI-DrugBank.d333.s7.p2
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Lipitor
|
Kadian
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p654
|
In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.
|
carbamazepine
|
Mefloquine
|
EFFECT
|
Mefloquine_ddi.xml
|
DDI-DrugBank.d220.s11
|
DDI-DrugBank.d220.s11.p13
|
Until data on possible interactions between verapamil and disopyramide phosphate are obtained, disopyramide should not be administered within 48 hours before or 24 hours after verapamil administration.
|
disopyramide
|
verapamil
|
ADVISE
|
Disopyramide_ddi.xml
|
DDI-DrugBank.d506.s9
|
DDI-DrugBank.d506.s9.p5
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
chlorpropamide
|
sulfamethoxazole
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p493
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
anticoagulant
|
cinchophen
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p11
|
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .
|
ondansetron
|
ondansetron
|
NONE
|
Apomorphine_ddi.xml
|
DDI-DrugBank.d357.s0
|
DDI-DrugBank.d357.s0.p19
|
Salicylic acid: Combination hormonal contraceptives may increase the clearance of salicylic acid.
|
hormonal contraceptives
|
salicylic acid
|
MECHANISM
|
Ethynodiol Diacetate_ddi.xml
|
DDI-DrugBank.d485.s38
|
DDI-DrugBank.d485.s38.p2
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
Acetaminophen
|
alprazolam
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p45
|
Use lowest possible dose of atorvastatin with careful monitoring, or consider HMG-CoA reductase inhibitors that are not primarily metabolized by CYP3A4, such as pravastatin, fluvastatin, or rosuvastatin in combination with CRIXIVAN.
|
atorvastatin
|
fluvastatin
|
NONE
|
Indinavir_ddi.xml
|
DDI-DrugBank.d97.s72
|
DDI-DrugBank.d97.s72.p2
|
Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.
|
diflunisal
|
acetaminophen
|
EFFECT
|
Diflunisal_ddi.xml
|
DDI-DrugBank.d132.s14
|
DDI-DrugBank.d132.s14.p0
|
The time to onset of maximum block following NIMBEX is approximately 2 minutes faster with prior administration of succinylcholine.
|
NIMBEX
|
succinylcholine
|
EFFECT
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s1
|
DDI-DrugBank.d60.s1.p0
|
MAO inhibitors prolong and intensify the anticholinergic effects of antihistamines.
|
MAO inhibitors
|
antihistamines
|
EFFECT
|
Cyproheptadine_ddi.xml
|
DDI-DrugBank.d492.s0
|
DDI-DrugBank.d492.s0.p0
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
EQUETROTM
|
praziquantel
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p32
|
Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase inhibition.
|
clorazepate dipotassium
|
ethyl alcohol
|
EFFECT
|
Clorazepate_ddi.xml
|
DDI-DrugBank.d335.s1
|
DDI-DrugBank.d335.s1.p1
|
As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.
|
antipsychotic agents
|
opiates
|
EFFECT
|
Haloperidol_ddi.xml
|
DDI-DrugBank.d186.s3
|
DDI-DrugBank.d186.s3.p3
|
Differential actions of intrathecal naloxone on blocking the tail-flick inhibition induced by intraventricular beta-endorphin and morphine in rats.
|
beta-endorphin
|
morphine
|
NONE
|
3155550.xml
|
DDI-MedLine.d63.s0
|
DDI-MedLine.d63.s0.p2
|
Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, Warfarin, etc.)
|
NSAIDs
|
Warfarin
|
NONE
|
Escitalopram_ddi.xml
|
DDI-DrugBank.d568.s3
|
DDI-DrugBank.d568.s3.p1
|
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
|
ciprofloxacin
|
sucralfate
|
MECHANISM
|
Ciprofloxacin_ddi.xml
|
DDI-DrugBank.d123.s8
|
DDI-DrugBank.d123.s8.p13
|
Fluconazole, an inhibitor of P450 2C9, decreased active metabolite concentration and increased losartan concentration.
|
Fluconazole
|
losartan
|
MECHANISM
|
Losartan_ddi.xml
|
DDI-DrugBank.d30.s4
|
DDI-DrugBank.d30.s4.p0
|
Administration of WELLBUTRIN Tablets to patients receiving either levodopa or amantadine concurrently should be undertaken with caution, using small initial doses and small gradual dose increases.
|
WELLBUTRIN
|
amantadine
|
ADVISE
|
Bupropion_ddi.xml
|
DDI-DrugBank.d5.s21
|
DDI-DrugBank.d5.s21.p1
|
In some patients, the administration of a non- steroidal antiinflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium- sparing and thiazide diuretics.
|
non- steroidal antiinflammatory agent
|
potassium- sparing diuretics
|
EFFECT
|
Ethacrynic acid_ddi.xml
|
DDI-DrugBank.d414.s6
|
DDI-DrugBank.d414.s6.p1
|
Investigations into the effect of acitretin on the protein binding of anticoagulants of the coumarin type (warfarin) revealed no interaction.
|
acitretin
|
warfarin
|
NONE
|
Acitretin_ddi.xml
|
DDI-DrugBank.d353.s14
|
DDI-DrugBank.d353.s14.p1
|
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).
|
Gleevec
|
clarithromycin
|
ADVISE
|
Imatinib_ddi.xml
|
DDI-DrugBank.d115.s0
|
DDI-DrugBank.d115.s0.p14
|
Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.
|
non-selective beta-adrenergic-blocking agents
|
antidiabetic drugs
|
EFFECT
|
Nateglinide_ddi.xml
|
DDI-DrugBank.d460.s14
|
DDI-DrugBank.d460.s14.p19
|
Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.
|
heroin
|
benzodiazepines
|
EFFECT
|
Heroin_ddi.xml
|
DDI-DrugBank.d514.s2
|
DDI-DrugBank.d514.s2.p2
|
Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.
|
FACTIVE
|
estrogen
|
MECHANISM
|
Gemifloxacin_ddi.xml
|
DDI-DrugBank.d347.s1
|
DDI-DrugBank.d347.s1.p3
|
Tetracycline, a bacteriostatic antibiotic, may antagonize the bactercidal effect of penicillin and concurrent use of these drugs should be avoided.
|
bacteriostatic antibiotic
|
penicillin
|
NONE
|
Dicloxacillin_ddi.xml
|
DDI-DrugBank.d517.s0
|
DDI-DrugBank.d517.s0.p2
|
Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.
|
kaolin
|
digoxin
|
MECHANISM
|
Digoxin_ddi.xml
|
DDI-DrugBank.d450.s6
|
DDI-DrugBank.d450.s6.p10
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
NIMBEX
|
bacitracin
|
EFFECT
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s12
|
DDI-DrugBank.d60.s12.p18
|
Therefore, proton pump inhibitors should be taken at least 30 minutes prior to sucralfate.
|
proton pump inhibitors
|
sucralfate
|
ADVISE
|
Lansoprazole_ddi.xml
|
DDI-DrugBank.d431.s8
|
DDI-DrugBank.d431.s8.p0
|
Antacids and kaolin: Antacids and kaolin can reduce absorption of chloroquine;
|
kaolin
|
chloroquine
|
NONE
|
Chloroquine_ddi.xml
|
DDI-DrugBank.d429.s0
|
DDI-DrugBank.d429.s0.p6
|
plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.
|
tricyclic antidepressants
|
phenytoin
|
MECHANISM
|
Clomipramine_ddi.xml
|
DDI-DrugBank.d238.s6
|
DDI-DrugBank.d238.s6.p4
|
Acetazolamide may increase the effects of other folic acid antagonists.
|
Acetazolamide
|
folic acid antagonists
|
EFFECT
|
Acetazolamide_ddi.xml
|
DDI-DrugBank.d368.s6
|
DDI-DrugBank.d368.s6.p0
|
Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;
|
Cholestyramine
|
fat soluble vitamins
|
MECHANISM
|
Calcidiol_ddi.xml
|
DDI-DrugBank.d98.s0
|
DDI-DrugBank.d98.s0.p27
|
Cyclosporine: Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with other members of the quinolone class.
|
cyclosporine
|
quinolone class
|
MECHANISM
|
Lomefloxacin_ddi.xml
|
DDI-DrugBank.d516.s15
|
DDI-DrugBank.d516.s15.p5
|
Use in Conjunction with Other Antiepileptic Drugs: The addition of Felbatol to antiepileptic drugs (AEDs) affects the steady-state plasma concentrations of AEDs.
|
Felbatol
|
AEDs
|
MECHANISM
|
Felbamate_ddi.xml
|
DDI-DrugBank.d434.s1
|
DDI-DrugBank.d434.s1.p5
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
cimetidine
|
pentoxifylline
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p563
|
Aminoglutethimide diminishes the effect of coumarin and warfarin.
|
coumarin
|
warfarin
|
NONE
|
Aminoglutethimide_ddi.xml
|
DDI-DrugBank.d372.s2
|
DDI-DrugBank.d372.s2.p2
|
It may increase excretion of barbiturates, lithium, and ASA and may also increase the toxicity of salicylates.
|
barbiturates
|
salicylates
|
NONE
|
Ethoxzolamide_ddi.xml
|
DDI-DrugBank.d286.s1
|
DDI-DrugBank.d286.s1.p2
|
Central Nervous System Depressants: The concomitant use of DURAGESIC (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
|
DURAGESIC
|
skeletal muscle relaxants
|
EFFECT
|
Fentanyl_ddi.xml
|
DDI-DrugBank.d170.s5
|
DDI-DrugBank.d170.s5.p21
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
naproxen
|
warfarin sodium
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p1274
|
The MPTP-induced neuronal damage produced a tolerance to the disruptive effects of amphetamine and a supersensitivity to the disruptive effects of apomorphine in rats responding in a schedule controlled paradigm.
|
MPTP
|
apomorphine
|
EFFECT
|
3871245.xml
|
DDI-MedLine.d73.s3
|
DDI-MedLine.d73.s3.p1
|
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
|
phenytoin
|
anticoagulants
|
EFFECT
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s19
|
DDI-DrugBank.d40.s19.p0
|
There is insufficient experience to assess the safety and efficacy of ORENCIA administered concurrently with anakinra, and therefore such use is not recommended.
|
ORENCIA
|
anakinra
|
ADVISE
|
Abatacept_ddi.xml
|
DDI-DrugBank.d297.s5
|
DDI-DrugBank.d297.s5.p0
|
Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.
|
FOSCAVIR
|
aminoglycosides
|
ADVISE
|
Foscarnet_ddi.xml
|
DDI-DrugBank.d511.s4
|
DDI-DrugBank.d511.s4.p4
|
Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);
|
glimepiride
|
Pepto-Bismol
|
ADVISE
|
Glimepiride_ddi.xml
|
DDI-DrugBank.d521.s1
|
DDI-DrugBank.d521.s1.p11
|
Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
|
quinolones
|
iron
|
MECHANISM
|
Grepafloxacin_ddi.xml
|
DDI-DrugBank.d78.s1
|
DDI-DrugBank.d78.s1.p7
|
The interaction is a consequence of blocking hepatic metabolism of vardenafil by ritonavir, a highly potent CYP3A4 inhibitor, which also inhibits CYP2C9.
|
vardenafil
|
ritonavir
|
MECHANISM
|
Vardenafil_ddi.xml
|
DDI-DrugBank.d198.s13
|
DDI-DrugBank.d198.s13.p0
|
Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.
|
PRECEDEX
|
sedatives
|
EFFECT
|
Dexmedetomidine_ddi.xml
|
DDI-DrugBank.d197.s1
|
DDI-DrugBank.d197.s1.p27
|
Fentanyl Anesthesia: Severe hypotension has been reported during fentanyl anesthesia with concomitant use of a beta blocker and a calcium channel blocker.
|
beta blocker
|
calcium channel blocker
|
NONE
|
Isradipine_ddi.xml
|
DDI-DrugBank.d81.s14
|
DDI-DrugBank.d81.s14.p5
|
Clinical experience with concomitant administration of bosentan and warfarin in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or warfarin dose (baseline vs. end of the clinical studies), and the need to change the warfarin dose during the trials due to changes in INR or due to adverse events was similar among bosentan- and placebo-treated patients.
|
bosentan
|
bosentan
|
NONE
|
Bosentan_ddi.xml
|
DDI-DrugBank.d289.s31
|
DDI-DrugBank.d289.s31.p3
|
Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.
|
SPRYCEL
|
ketoconazole
|
MECHANISM
|
Dasatinib_ddi.xml
|
DDI-DrugBank.d48.s1
|
DDI-DrugBank.d48.s1.p0
|
No significant interactions with digoxin, hydrochlorothiazide, hydralazine, sulfinpyrazone, oral contraceptives, tolbutamide, or warfarin have been observed.
|
digoxin
|
hydrochlorothiazide
|
NONE
|
Acebutolol_ddi.xml
|
DDI-DrugBank.d388.s5
|
DDI-DrugBank.d388.s5.p0
|
Central Nervous System Depressants: The concomitant use of DURAGESIC (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
|
fentanyl
|
benzodiazepines
|
EFFECT
|
Fentanyl_ddi.xml
|
DDI-DrugBank.d170.s5
|
DDI-DrugBank.d170.s5.p28
|
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .
|
apomorphine
|
ondansetron
|
ADVISE
|
Apomorphine_ddi.xml
|
DDI-DrugBank.d357.s0
|
DDI-DrugBank.d357.s0.p25
|
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.
|
benzodiazepines
|
nifedipine
|
INT
|
Alprazolam_ddi.xml
|
DDI-DrugBank.d131.s10
|
DDI-DrugBank.d131.s10.p5
|
MAO inhibitors: MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism.
|
MAO inhibitors
|
MAOI antidepressants
|
NONE
|
Dextroamphetamine_ddi.xml
|
DDI-DrugBank.d236.s10
|
DDI-DrugBank.d236.s10.p0
|
Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
|
acetaminophen
|
narcotic analgesic
|
EFFECT
|
Butalbital_ddi.xml
|
DDI-DrugBank.d559.s1
|
DDI-DrugBank.d559.s1.p10
|
Therefore, when Hydrochlorothiazide and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.
|
Hydrochlorothiazide
|
non-steroidal anti-inflammatory agents
|
ADVISE
|
Hydrochlorothiazide_ddi.xml
|
DDI-DrugBank.d162.s13
|
DDI-DrugBank.d162.s13.p0
|
Methenamine therapy Urinary excretion of amphetamines is increased, and efficacy is reduced by acidifying agents used in methenamine therapy.
|
amphetamines
|
methenamine
|
MECHANISM
|
Lisdexamfetamine_ddi.xml
|
DDI-DrugBank.d158.s17
|
DDI-DrugBank.d158.s17.p2
|
Acetaminophen: In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen.
|
diflunisal
|
acetaminophen
|
MECHANISM
|
Diflunisal_ddi.xml
|
DDI-DrugBank.d132.s11
|
DDI-DrugBank.d132.s11.p3
|
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.
|
retinoids
|
insulin
|
EFFECT
|
3881461.xml
|
DDI-MedLine.d12.s7
|
DDI-MedLine.d12.s7.p12
|
Macrolide Antibiotics (e. g. erythromycin and troleandomycin): Agents of the ergot alkaloid class, of which D.H.E. 45 (dihydroergotamine mesylate) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.
|
D.H.E. 45
|
macrolide class
|
MECHANISM
|
Dihydroergotamine_ddi.xml
|
DDI-DrugBank.d410.s5
|
DDI-DrugBank.d410.s5.p24
|
Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.
|
diclofenac
|
prednisolone
|
MECHANISM
|
Diclofenac_ddi.xml
|
DDI-DrugBank.d249.s18
|
DDI-DrugBank.d249.s18.p2
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.